Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Dermatology

Date Submitted: Dec 21, 2020
Date Accepted: Apr 17, 2021
Date Submitted to PubMed: Aug 26, 2023

The final, peer-reviewed published version of this preprint can be found here:

Development of an mHealth App for Patients With Psoriasis Undergoing Biological Treatment: Participatory Design Study

Trettin B, Danbjørg DB, Andersen F, Feldman S, Agerskov H

Development of an mHealth App for Patients With Psoriasis Undergoing Biological Treatment: Participatory Design Study

JMIR Dermatol 2021;4(1):e26673

DOI: 10.2196/26673

PMID: 37632817

PMCID: 10501531

Development of an mHealth application for patients with psoriasis on biological treatment: A participatory design study

  • Bettina Trettin; 
  • Dorthe Boe Danbjørg; 
  • Flemming Andersen; 
  • Steven Feldman; 
  • Hanne Agerskov

ABSTRACT

Background:

In Denmark, psoriasis patients on biological treatment have regular follow-ups, typically every three months. This may be a challenge for patients who live far away from the hospital. Mobile health (mHealth) can be a promising and reliable tool for the long-term management of psoriasis patients on biological treatment, because the disease course can be properly monitored. Despite the recent developments in mHealth, the full potential of teledermatology remains to be tapped by newer, more attractive forms of services, focused on patients’ needs.

Objective:

To design and develop an mHealth app to support psoriasis patients’ self-management using participatory design.

Methods:

Using Participatory design, we conducted one future workshop, four mock-up workshops and one prototype test with patients and healthcare professionals were conducted to co-design a prototype. The process was iterative to ensure that all stakeholders would have a say in the design and outcome; it enabled continuous revision of the prototype until an acceptable solution was agreed upon. Data were analyzed according to the plan, act, observe and reflect methodology of participatory design.

Results:

Health care professionals and patients emphasized the importance of a more patient-centered approach, focusing on communication and the maintenance of relationships. Patients perceived consultations to be impersonal and repetitive, and wanted the opportunity to contribute to the agenda when attending a consultation. Patients would also prefer not to have to attend in person every three months. Based on these findings, we designed an mHealth application that could both replace in-person visits and support patients at in-person visits. Video consultations, self-monitoring, and registration of patient-reported outcome data were all embedded in the application.

Conclusions:

Using participatory design facilitated mutual learning and democratic processes that gave the end-users significant influence over the solution. Despite the advantages of using participatory design in the development of mHealth solutions, organizational conditions may still represent a barrier to optimization of solutions.


 Citation

Please cite as:

Trettin B, Danbjørg DB, Andersen F, Feldman S, Agerskov H

Development of an mHealth App for Patients With Psoriasis Undergoing Biological Treatment: Participatory Design Study

JMIR Dermatol 2021;4(1):e26673

DOI: 10.2196/26673

PMID: 37632817

PMCID: 10501531

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.